Synchron

Synchron is a neurotechnology company based in New York, founded in 2012. It specializes in implantable brain-computer interfaces (BCIs) designed to enable thought-controlled digital devices for individuals with paralysis or severe physical disabilities. The company focuses on developing minimally invasive endovascular implants that can be deployed without open brain surgery, allowing users to regain autonomy in tasks such as texting and controlling smart home devices. The flagship product, Stentrode, is a permanent BCI implanted in the brain's blood vessels. It captures neural signals and translates thoughts into digital motor outputs for hands-free device control. Synchron also recently launched Chiral, a foundation model for cognitive AI applications, aimed at research and pharmaceutical sectors. The company has successfully implanted its BCI in 10 patients since 2019 and emphasizes practical usability and patient-first design. With a team led by CEO Tom Oxley, Synchron has received multiple awards for its innovations and maintains partnerships with major tech companies like Apple and Amazon.